Format

Send to

Choose Destination
Eur J Cancer. 2013 Jul;49(11):2531-41. doi: 10.1016/j.ejca.2013.04.005. Epub 2013 May 3.

Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13.

Author information

1
EA4340 'Epidémiologie et Oncogénèse des tumeurs digestives', Versailles Saint-Quentin-en-Yvelines University, 78280 Guyancourt, France; Hepato-Gastroenterology Department, Pitié Salpêtrière Hospital, 75013 Paris, France; Medical University Pierre et Marie Curie, UFR Paris VI, France.
2
Hepato-Gastroenterology and Digestive Oncology Department, European Georges Pompidou Hospital, 75015 Paris, France.
3
Medical University Paris Descartes, INSERM UMR-S775 Unit, 75006 Paris, France; Oncogenetic Department, European Georges Pompidou Hospital, APHP, 75015 Paris, France.
4
Oncology Department, CRLC Bergonié, 33076 Bordeaux, France.
5
Department of Medical Oncology, Gustave Roussy Institute, 94800 Villejuif, France.
6
Gastroenterology and Pancreatology Department, Beaujon Hospital, 92110 Clichy, France.
7
Hematology Department, Henri Mondor Hospital, 94010 Créteil, France.
8
Oncology Department, La Timone Hospital, 13354 Marseille Cedex 5, France.
9
Oncology Department, Léon Bérard Center, 69373 Lyon Cedex 08, France.
10
EA4340 'Epidémiologie et Oncogénèse des tumeurs digestives', Versailles Saint-Quentin-en-Yvelines University, 78280 Guyancourt, France; Pathology Department, Ambroise Paré Hospital, APHP, 92100 Boulogne, France. Electronic address: jean-francois.emile@uvsq.fr.

Abstract

BACKGROUND:

The demonstration of the role of activating mutations of KIT or PDGFRA and the development of targeted therapies have modified the prognosis of patients with gastrointestinal stromal tumours (GISTs). Identification of kindreds with KIT or PDGFRA germline mutation raised new questions, especially regarding the diagnosis, management, monitoring and treatment of these patients.

METHODS:

We identified index patients of three different families with a KIT exon 13 germline mutation. Pedigree of GIST kindred was assessed in oncogenetic consultation, and medical records were reviewed. Efficacy of imatinib in GISTs with KIT exon 13 was evaluated and compared with published data.

RESULTS:

All KIT germline mutations were p.K642E. Twenty affected patients were identified in the three families. GISTs were multiple and occurred before 45years in all but one case. All resected tumours were of spindle cell histology, CD117 positive, and had low or intermediate risk of relapse. Lentigines involving the palms and soles were detected in four patients, and three patients had motrice dysphagia. Nine affected patients died of their disease, all but one before 65years. Affected patients were most often symptomatic and required iterative surgical resections. Imatinib was efficient in GISTs with p.K642E mutation with a disease control rate superior to 90% whatever the sporadic or inherited origin of the tumour.

CONCLUSIONS:

We propose a regular screening of kindreds who have germline mutation. Treatment with imatinib should be considered for those with symptomatic tumour, larger than 3cm and/or growing rapidly.

PMID:
23648119
DOI:
10.1016/j.ejca.2013.04.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center